DexCom (NASDAQ:DXCM) Given New $75.00 Price Target at TD Cowen

DexCom (NASDAQ:DXCM) had its target price reduced by TD Cowen from $84.00 to $75.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the medical device company’s stock.

Several other equities research analysts have also issued reports on DXCM. Wells Fargo & Company dropped their price target on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Truist Financial reiterated a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Robert W. Baird set a $80.00 price objective on DexCom in a report on Friday. Finally, Barclays set a $67.00 price objective on DexCom and gave the stock an “underweight” rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $83.73.

DexCom Price Performance

DXCM stock traded up $1.80 during mid-day trading on Friday, hitting $61.35. 10,561,408 shares of the stock were exchanged, compared to its average volume of 4,160,611. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The business has a fifty day moving average price of $65.87 and a 200 day moving average price of $66.40. DexCom has a 12 month low of $54.11 and a 12 month high of $89.98. The stock has a market capitalization of $23.67 billion, a price-to-earnings ratio of 29.21, a PEG ratio of 1.16 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 34.18% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. The company’s revenue was up 15.0% compared to the same quarter last year. On average, sell-side analysts anticipate that DexCom will post 2.49 EPS for the current year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DXCM. Brighton Jones LLC increased its holdings in DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC increased its holdings in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the period. Empowered Funds LLC increased its holdings in DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth increased its holdings in DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares during the period. Finally, NewEdge Advisors LLC increased its holdings in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after purchasing an additional 258 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 beat on both EPS and revenue; non‑GAAP EPS of $0.56 topped estimates and revenue rose 15% to $1.19B with margins improving — a clear near‑term earnings beat that supports upside. DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
• Positive Sentiment: Company reported record new patient starts globally and cites product momentum plus coverage expansion as drivers — supports sustained top‑line growth and market penetration for its CGM franchise. DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
• Positive Sentiment: Medicare National Coverage Determination (NCD) remains the biggest catalyst for 2026 per RBC — a favorable NCD could materially expand U.S. addressable market and is being watched by investors. DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says
• Neutral Sentiment: Management reaffirmed FY26 revenue guidance (~$5.2–$5.3B) rather than raising it; that keeps the outlook intact but removes an upside surprise for the full year amid geopolitical caution. Dexcom reaffirms full-year forecast after topping quarterly estimates
• Negative Sentiment: Some brokerages trimmed price targets (TD Cowen cut to $75; BTIG lowered its PT to $80) even as they keep Buy ratings — reduces near‑term analyst upside and may cap gains. Benzinga
• Negative Sentiment: Shares saw an after‑hours pullback in some sessions despite the beat as investors parsed the lack of an upgraded FY revenue outlook and geopolitical risk; watch volume and guidance commentary in the call transcript/slides. Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.